Αποτελέσματα Αναζήτησης
2 Απρ 2024 · Universal vaccination: To reduce community transmission and protect individuals with HIV, this committee agrees with the CDC recommendations for universal vaccination against COVID-19 for adults (≥18 years old) with HIV, regardless of prior history of COVID-19 infection.
EACS produces Guidelines for the management of people living with HIV in Europe. The English version is regularly updated by the guidelines panels with major revision every other year and minor revisions in the years in between. Guidelines are published in the autumn and translated into additional languages.*
10 Ιαν 2024 · For people with HIV without risk factors, waiting for a CD4 count >200 cells/mm 3 is an option. Assess antibody response 1 to 2 months after completion of the series. If negative, revaccinate when the CD4 count is >200 cells/mm 3 (BIII).
5 Μαΐ 2023 · As prevention and treatment modalities in HIV care expand (i.e., vaccines, barriers, injectables, implants, on-demand therapies), it is important for clinicians to ask patients about their goals for prevention and treatment rather than assume that efficacy is the primary factor in patient preference [Sewell, et al. 2021].
In this review, we summarize the most recent HIV vaccine efficacy trials, clinical trials initiated within the last 3 years, and discuss prominent improvements that have been made in prophylactic HIV vaccine designs.
1. Introduction. Much has happened in the field of human immunodeficiency virus-1 (HIV) vaccine research in recent years. The field of vaccinology has advanced considerably in the last decade, giving rise to novel vaccines for human pathogens. HIV is a pathogen that has challenged vaccine researchers for over 30 years.
22 Νοε 2021 · Vaccines. The Panel responsible for maintaining the  Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV published an update to the section on immunizations on November 18, 2021. Highlights of the update include:
